ArticleFrontiers in medicine2026
Rheumatoid arthritis and cardiovascular disease in relation to cytomegalovirus infection: a pilot cross-sectional study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with rheumatoid arthritis (RA) face increased cardiovascular disease (CVD) risk not fully explained by traditional factors. Chronic cytomegalovirus (CMV) infection may contribute through immune activation and vascular inflammation. This pilot study investigated associations between CMV serostatus, vascular endothelial growth factor A (VEGF-A), and inflammatory markers in patients with RA and/or CVD. Methods: This cross-sectional study enrolled 76 participants (CVD = 40, RA = 18, RA+CVD = 18). Serum anti-CMV antibodies, VEGF-A, and IL-6 were measured by ELISA; CRP was assessed by agglutination; and CMV viral load was quantified by RT-PCR. Group comparisons analyses were performed. Results: CMV seroprevalence was 80.3% overall (CVD: 82.5%; RA: 77.8%; RA+CVD: 77.8%). VEGF-A levels were higher in CMV positive vs. CMV negative individuals, but the differences were not statistically significant; these data are inconclusive regarding a true association (e.g., overall mean: 67.8 vs. 44.5 pg/mL, Conclusions: This pilot study is underpowered for definitive conclusions and should be interpreted as exploratory and hypothesis-generating. Although VEGF-A levels were higher in CMV positive individuals, the association was not statistically significant and the data are inconclusive. Larger, adequately powered studies are needed to clarify the role of CMV and angiogenic pathways in RA associated CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.